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Abstract
Introduction After endoscopic resection (ER) of neoplasia in Barrett’s esophagus (BE), it is recommended to ablate the remaining
BE to minimize the risk for metachronous disease. However, we report long-term outcomes for a nationwide cohort of all patients
who did not undergo ablation of the remaining BE after ER for early BE neoplasia, due to clinical reasons or performance status.
Methods Endoscopic therapy for BE neoplasia in the Netherlands is centralized in 8 expert centers with specifically trained
endoscopists and pathologists. Uniformity is ensured by a joint protocol and regular group meetings. We report all patients who
underwent ER for a neoplastic lesion between 2008 and 2018, without further ablation therapy. Outcomes include progression
during endoscopic FU and all-cause mortality.
Results Ninety-four patients were included with mean age 74 (± 10) years. ER was performed for low-grade dysplasia (LGD)
(10%), high-grade dysplasia (HGD) (25%), or low-risk esophageal adenocarcinoma (EAC) (65%). No additional ablation was
performed for several reasons; in 73 patients (78%), the main argument was expected limited life expectancy. Median C2M5 BE
persisted after ER, and during median 21 months (IQR 11–51) with 4 endoscopies per patient, no patient progressed to advanced
cancer. Seventeen patients (18%) developed HGD/EAC: all were curatively treated endoscopically. In total, 29/73 patients (40%)
with expected limited life expectancy died due to unrelated causes during FU, none of EAC.
Conclusion In selected patients, ER monotherapy with endoscopic surveillance of the residual BE is a valid alternative to
eradication therapy with ablation.
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Introduction
Barrett’s esophagus (BE) is the most important risk factor for
esophageal adenocarcinoma (EAC), which has a poor prog-
nosis. Identifying EAC at an early stage allows for endoscopic
treatment with an excellent prognosis. The first step in endo-
scopic treatment for BE-related neoplasia is removal of all
visible lesions with endoscopic resection (ER) techniques,
which serves both diagnostic and therapeutic purposes. It
has been reported that the remaining flat BE that persists after
ER of a neoplastic lesion has a risk of developing
metachronous HGD/EAC between 15 and 30% in 3–5 years
1–3. Based on these data, most international guidelines advise
additional ablation therapy after ER to eradicate the entire BE
segment 4–7. Given the large amount of high-quality data
supporting radiofrequency ablation (RFA), this is recom-
mended as first-choice ablation technique 4, 8–10.
Although RFA therapy is highly effective for eradication of
flat BE, the choice to continue with ablation requires balanced
decision-making, taking into account patient’s age, comorbid-
ity, and life expectancy 6. The aforementioned FU studies
have also shown that metachronous lesions were always de-
tected at early stages that allowed curative endoscopic treat-
ment 1–3. Moreover, the majority of patients will never devel-
op metachronous neoplasia. Performing RFA for all post-ER
patients may thus be associated with overtreatment.
Although severe complications due to RFA treatment are
very rare, complications do occur, most commonly esophage-
al strictures in up to 10–14% 11. Furthermore, RFA treatment
to eradicate all residual BE requires on average 3 additional
therapeutic endoscopies. Patients may experience post-
procedural pain, discomfort, or dysphagia. Therefore, after
ER for early neoplasia, endoscopic surveillance (“ER mono-
therapy”) may be an acceptable alternative to RFA, especially
in patients with older age and/or severe comorbidities.
In the Netherlands, endoscopic treatment for BE is central-
ized in 8 Barrett Expert Centers (BECs), with a uniform treat-
ment and follow-up protocol. Since the introduction of RFA in
2008, these centers adhered to the ER monotherapy strategy in
selected patients. In the current study, we report the long-term
outcomes of “ER monotherapy” as an alternative to additional
ablation therapy in patients with limited life expectancy.
Methods
This study was based on the Barrett Expert Center registry
(BEC registry) (Netherlands Trial Register, NL7039), which
has been described in detail earlier 12. In short, this registry
captures outcomes for all patients with Barrett’s neoplasia in
the Netherlands who underwent endoscopic treatment since
2008. Care for BE neoplasia in the Netherlands is centralized
in 8 Barrett Expert Centers (BECs), with the implication that
every patient in the Netherlands is treated in one of these
expert centers. This centralized organization of care was
established in 2007. At that moment, a joint training program
was launched for endoscopists and pathologists, one of both
from each center. All BE care in the Netherlands since then
has been provided by the specifically trained endoscopists and
pathologists. The BECs adhered to a common treatment and
follow-up protocol, and several meetings a year were held to
further guarantee homogeneity. Apart from this close collab-
oration for clinical care, a solid joint research infrastructure
was founded and resulted in multiple publications in the field
of pathology 13–16, imaging 17–19, and treatment 8, 9, 20–26 of
early BE neoplasia.
The centers have a minimum annual case load of 10 new
patients with neoplasia per year, and all new cases are regis-
tered in a database.
Treatment Protocol
Patients were referred to a BEC for careful work-up and stag-
ing after being diagnosed with low-grade dysplasia (LGD),
HGD, or EAC. During an upper gastrointestinal endoscopy
(UGE), the esophagus was carefully inspected with documen-
tation of the Prague C&M criteria and presence of visible
lesions or other abnormalities such as esophagitis or esopha-
geal stenosis.
If a visible abnormality was detected, endoscopic resection
(ER) was performed for histologic staging using the ER-cap
technique, multiband mucosectomy (MBM), or endoscopic
submucosal dissection (ESD) per physician’s discretion.
Four-quadrant random biopsies were obtained from the
(residual) flat BE segment according to the Seattle protocol 27.
If the ER specimen showed LGD, HGD, or low-risk (LR)
EAC (defined as ≤sm1 invasion with good to moderate dif-
ferentiation, without lymphovascular invasion and with radi-
cal vertical resection margin), a balanced decision was made
between further endoscopic treatment or surveillance. In the
vast majority of patients, additional ablation therapy was of-
fered to achieve a complete eradication of the entire Barrett’s
segment. However, in patients with limited life expectancy,
for example, due to older age and/or severe comorbidity, sur-
veillance of the remaining BE was preferred with endoscopic
intervention in case of recurrent neoplasia and/or visible
lesions.




FU for persisting non-dysplastic BE (NDBE)/LGD after ER
consisted of yearly surveillance endoscopies in year 1 to 5,
and then once per 2–3 years. FU was performed every 3–6
months for persisting HGD. The decision to stop further sur-
veillance was made per physician’s discretion in agreement
with the patient.
Study Population
For the current study, we included all patients from the BEC
registry who underwent ER monotherapy for LGD, HGD, or
LR-EAC with residual flat BE before January 1, 2018.
Study Endpoints
The first primary endpoint was progression to HGD/EAC in
the remaining BE. For patients with remaining NDBE or
LGD, detection of HGD/EAC was considered to be progres-
sion. For patients with persisting flat HGD, new EAC was
progression as was a new visible lesion containing HGD.
All patients were included for this analysis. This endpoint
was stratified for residual grade of dysplasia.
The second primary endpoint was all-cause mortality. This
endpoint reflects whether the decision to prefer surveillance
over ablation was justified for patients with expected limited
life expectancy. Therefore, only the patients in whom the de-
cision for ER monotherapy was based on age and/or comor-
bidity were included for this analysis.
Secondary endpoints included symptomatic EAC and/or
EAC-related death and predictors for progression. All patients
were included for these analyses. We also assessed progres-
sion risk to HGD/EAC in the remaining BE among only pa-
tients who had at least 18 months of endoscopic FU.
Data Collection and Data Management
Endoscopy and pathology data were collected in standardized
form in all BECs, by medical students in the final year of their
degree. Additionally, all patients with endpoints and an addi-
tional 50% of the remaining patients were double-checked by
dedicated research fellows (all MDs). All fields were exam-
ined for missing data, unlogical values, or outliers, with data
being completed or corrected where possible.
The BEC registry was merged with the non-public
microdata from Statistics Netherlands for date and cause of
death.
Statistics
Continuous variables were presented as mean with standard
deviation (SD) or median with interquartile range (IQR) for
normally distributed or skewed data, respectively. Categorical
variables were presented as numbers with percentages, and
95% confidence intervals (CI) were obtained using internal
bootstrapping.
Progression risks were plotted using the cumulative inci-
dence curve (CII), taking competing risks of unrelated death
into account. Annual progression rates were calculated as the
number of progressors divided by the total follow-up duration
in years. Predictors for progression were assessed using Cox
regression and Fine and Gray competing risk analysis, the
latter considered unrelated death as competing risk.
Statistical analysis was performed using Rstudio for
Windows (version 3.6.1) and packages: survival, survminer,
cmprsk, ggplot2, and Hmisc.
Ethics
The Institutional Review Board of the Amsterdam University
Medical Centers declared that the registry was not subject to
the Medical Research Involving Human Subjects Act (“wet
op medisch-wetenschappelijk onderzoek met mensen” in
Dutch) and waived the need for formal ethical review and
patient-informed consent. Patients were approached through
an opt-out card with the possibility to object against participa-
tion in the registry.
Results
Patient Description
Between 2008 and 2018, a total of 1962 patients with early BE
neoplasia were referred to a BEC. A visible abnormality was
detected in 1395 patients (71%) and removed with ER (Fig. 1).
After ER for LGD, HGD, or LR-EAC (n = 1140), a flat BE
segment remained in 1034 patients. The vast majority of these
patients (91%) underwent additional ablation aimed at eradi-
cation of the entire BE segment. Ninety-four patients (9%) had
ERmonotherapy for LGD (n = 9), HGD (n = 23), T1a EAC (n
= 47), or T1bsm1 EAC (n = 15), with remaining BE, and were
included for this study.
Patients had a mean age of 74 (± 10) years and ASA clas-
sification II (67%) or III/IV (23/2%), with ER performed for
LGD (10%), HGD (25%), or LR-EAC (66%) (Table 1).
Decision-Making After ER
After ER for all visible abnormalities, a flat BE segment of
median C2M5 (0–5; 3–8) remained with NDBE (n = 48,
51%), LGD (n = 29, 32%), or HGD (n = 6, 6%). In 11 patients
(12%), no biopsies were obtained since this was considered
not to change clinical decision-making.
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In 73 patients (78%), additional ablation was not started
due to age and/or comorbidity. Concomitant reasons in this
group were as follows: expected poor regression after RFA
due to regeneration with BE after ER (n = 8, 11%); patient
preference (n = 7, 10%); persistence of a small BE tongue only
(n = 5, 7%); and/or complications after ER (n = 3, 4%) (Fig.
2).
In the remaining 21 patients (22%) in whom age and co-
morbidity played no role, reasons not to continue with abla-
tion therapy were as follows: other treatment protocols (e.g.,
in the pre-RFA era) (n = 11, 52%); persistence of a small BE
tongue only (n = 6, 29%); expected poor regression after RFA
due to BE regeneration after ER (n = 3, 14%); complications
after ER (n = 1, 5%); and/or patient preference (n = 1, 5%).
Progression During Follow-Up
During a median endoscopic FU of 21 months (11–51) with a
median of 4 endoscopies 3–5 per patient, no patient progressed to
advanced cancer. Overall, 17 patients (18%, annual progression
risk 8.0% [95% CI 5.1–12.5]) progressed to HGD (n = 10) or
LR-EAC (n = 7) (Table 2). The median time to progression was
26 months (23–47), and the first progression was detected 18
months after ER. All patients who progressed had undergone at
least 2 FU endoscopies without abnormalities after ER.
Sixteen out of seventeen progressors were successfully treat-
ed endoscopically, either with ER for a visible lesion containing
LR-EAC (n = 7) or HGD (n = 6) or with ablation therapy for flat
HGD (n = 3). A single patient who progressed from LGD to
HGD had no further treatment, and the patient died shortly after
due to an unrelated cause. Six progressors had developed a
worse histological grade during FU, than the initial histology
after baseline ER. This included baseline LGD to m-EAC in
FU (n = 1), baseline HGD with m-EAC in FU (n = 4), and
baseline m-EAC with sm-EAC during FU (n = 1).
The annual risk for progression was 6.4% for residual
NDBE and 6.7% for LGD, as compared to 14.5% for residual
HGD (Table 2).
In total, 55 patients had an endoscopic FU > 18 months
with an annual risk for progression of 8.6% per person year
[95% CI 5.4–13.3]. The median FU in this subgroup of pa-
tients was 31 months after ER (IQR 17–53).
In the majority (27/39; 69%) of the patients with FU < 18
months, endoscopic FU was discontinued at median 3 months
(IQR 0–9) after ER, due to limited life expectancy. Of these 27
patients, 15 had unrelated death median 18 months after ER,
whereas the remaining 12 were alive and asymptomatic at
median 55 months after ER. The remaining 12/39 patients
with short FU were recently treated with ER and were still
under endoscopic surveillance (median 12 months).
All-Cause Mortality
Our second aim was to asses all-cause mortality during long-
term follow-up in the subgroup of patients with older age and/
or comorbidity, to verify whether ER monotherapy was justi-
fied in this group of patients.
As reported, in 73 patients, age and/or comorbidity played an
important role in the decision not to continue with ablation ther-
apy after ER. In 37 patients, endoscopic surveillancewas stopped
early at median 20 months (5–59) after ER (Fig. 3). Unrelated
death occurred in 16 of these patients median 10months after FU
was stopped. The remaining 21 patients were still alive and
asymptomatic median 24 months after FU was stopped.
In the remaining 36 patients, endoscopic FU was not
stopped early. A total of 13 patients died from unrelated
causes while being under surveillance, median 50 months af-
ter ER. The remaining 23 patients were still under surveillance
at the moment of data collection, median 21 months after ER.
Overall, 29 of 73 patients (40%) died due to unrelated
causes median 28 months after ER at a median age of 80
(72–85) years. The remaining 44 of 73 patients were still alive
at the moment of data collection median 42 months after ER.
Figure 4 shows the cumulative incidence curves for progres-
sion and unrelated death. Neoplasms other than EAC (n = 11,
BE with visible lesion 
N = 1,395
BE and lesion with 
LGD/HGD/LR-EAC
N = 1,140
High-risk EAC, n = 255














Flat BE with dysplasia
N = 567
Fig. 1 Flowchart. Patient flow in the Barrett Expert Center Registry. All
patients with remaining flat BE after ER for which no ablation was
performed were included in the current study (n = 94)
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38%) and cardiovascular disease (n = 11, 38%) contributed
the most common causes of death.
EAC-Related Death
None of the 94 patients progressed to disease stages that
exceeded boundaries for curative endoscopic treatment,
developed symptomatic EAC, or died from EAC.
Predictors
In univariable analysis, length of the residual BE was signifi-
cantly associated with risk for progression during FU (Table 3).
For patients with a remaining circumferential BE of 0–1 cm, 2–
5, or > 5 cm, the annual progression risks were 1.8%, 7.0%, and
15.9%, respectively. The risk increased with 11% for every
centimeter increase in BE length. The hazard ratio for persisting
HGD versus LGD or NDBE was considerable, but did not
Table 1 Demographics
All N = 1034 ERmonotherapy N = 94 ER + ablation N = 940
Male gender, n (%) 803 (80) 64 (86) 766 (82)
Age, years (mean (± SD)) 66 (10) 74 (10) 65 (9)
BMI, kg/m2 (mean (± SD)) 28 (5) 27 (10) 27 (5)






Current 169 (23) 12 (18) 157 (23)
Former 338 (46) 37 (56) 301 (45)
Never 232 (31) 17 (26) 215 (32)
Esophagitis, n (%) 36 (4) 2 (2) 34 (4)
BE segment, cm (median (IQR)) C2M5 (1–5; 3–7) C4M6 (1–7; 3–9) C2M5 (1–5; 3–7)
Lesion, Paris-type, n (%)
0-Ip/s 107 (13) 17 (24) 90 (12)
0-IIa 563 (67) 35 (50) 528 (69)
0-IIb 131 (16) 15 (21) 116 (15)
0-IIc 35 (4) 3 (4) 32 (4)
Lesion, size, mm (mean (± SD)) 25 (15) 27 (21) 25 (15)
Lesion, circ extent, % (mean (± SD)) 39 (21) 39 (21) 39 (21)
ER type, n (%)
EMR 983 (95) 85 (90) 898 (96)
ESD 49 (5%) 7 (7) 42 (5)
Both 2 (0.2%) 2 (2) 0
Specimen ER, N (median (IQR)) 2 (1–3) 2 (1–3) 2 (1–3)
< 50% squamous regression
of ER-site, n (%)
53 (5) 12 (13) 41 (5)
Worst ER pathology, n (%)
LGD 69 (7) 9 (10) 60 (6)
HGD 263 (25) 23 (25) 240 (26)
EAC 702 (68) 62 (66) 640 (68)
*Missing values existed for the following variables (n = missing in total cohort/missing in ER monotherapy
cohort): BMI (n = 164/25), ASA (n = 700/0), smoking (n = 295/28), Paris classification (n = 198/24), and
regeneration of ER site (n = 56/0)
ASAAmerican Society of Anesthesiologists, BEBarrett esophagus, circ circumferential, EAC(-m/sm) esophageal
adenocarcinoma (mucosal/submucosal), EMR endoscopic mucosal resection, ER endoscopic resection, ESD
endoscopic submucosal dissection, HGD high-grade dysplasia, IQR interquartile range, LGD low-grade dyspla-
sia, SD standard deviation
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reach the level of statistical significance. Estimated hazard ra-
tios for Fine and Gray and Cox analysis were comparable.
Discussion
We report endoscopic and long-term all-cause mortality out-
comes for all patients with ER monotherapy in the
Netherlands between 2008 and 2018, to assess whether this
is a justified treatment strategy in selected patients with early
BE neoplasia, for example, in case of older age and/or signif-
icant comorbidity. The risk for progression to HGD or EAC
was 8% per year. In all cases, progression was detected at
early stages and curatively treated endoscopically. No patient
developed advanced EAC, and no patient died due to EAC,
even though endoscopic surveillance was stopped early in half
of the patients. Overall, 40% of patients died due to EAC
unrelated causes at median 28 months after ER. These data
suggest that ER monotherapy with endoscopic surveillance of
the residual BE is a valid alternative to prophylactic ablation
therapy in selected patients.
Data from the current study comport well with older studies
from the pre-ablation era, reporting progression rates in re-
maining flat BE after ER varying from 15 during 5 years to
30% in 3 years 1–3. These data have generally been used to
justify initiating ablation therapy after ER, but one could also
look at it from a different point of view. During every year of
FU after ER, only 8% of patients develop progression, and this
was always curatively treated with a single ER.
RFA is effective and can achieve complete eradication of
all BE (CE-BE) in 90–95% of patients. However, RFA is
associated with multiple hospital visits and a risk of compli-
cations. Patients with baseline ER have the highest risk for
post-RFA stenosis 28. Apart from RFA-related complications,
a recent study showed that the risk for cardiovascular compli-
cations due to sedation increases with age 29. Unfortunately,













NDBE LGD HGD LR-
EAC
No biopsies 11 17 (8–65) 3 (1–6) 5 5 1 0 0 –
NDBE 48 20 (10–48) 3 (1–5) 0 37 3 3 5 6.4% [3.3–12.1]
LGD 29 22 (14–60) 3 (1–5) 1 13 9 (4*) 5 1 6.7% [3.1–13.9]
HGD 6 41 (14–62) 7 (2–10) 0 0 0 5 (2**) 1 14.5% [5.0–34.6]
Total 94 21 (11–51) 3 (1–5) 6 54 13 13 7 8.0% [5.1–12.5]
Risk for progression to HGD/EAC during endoscopic FU, stratified for histology of the flat BE that remained after ER
*4 with persisting LGD were treated with RFA
**2 with HGD developed a lesion during FU and were treated with ER and counted as progression
Fig. 2 Reasons not to continue
with ablation therapy after ER.
Several reasons were reported
why RFA was not initiated; age
and/or comorbidity constituted
the most common reasons
J Gastrointest Surg
we could not evaluate these endpoints in the current study
given its retrospective nature with a risk for underreporting
of these complications.
The decision to initiate prophylactic ablation therapy of
residual BE after ER of neoplasia should be based on the
answers to the following three questions:
1 What is the risk for this patient to develop recurrent neo-
plasia, with or without ablation therapy?
A substantial proportion of patients will never develop neo-
plasia in the remaining BE after ER. If the remaining BE after
ER contains NDBE or LGD, the annual progression risk was
only 6.4–6.7%. The median BE length in the current study
was C2M5, and for shorter BE lengths, this annual risk will
be even lower 1. Apart from the annual risk, we should also
consider the cumulative risk for progression. Assume we con-
tinue surveillance until the age of 80 years, then the cumula-
tive risk for a 50-year-old patient will be much higher as
compared to a 78-year-old patient. Furthermore, if RFA treat-
ment is initiated, it is important to realize that the risk for
future neoplasia is lowered, but not reduced to zero. RFA
generally fails to achieve CE-BE in 5–10% of patients, and
the annual risk for recurrent neoplasia after CE-BE is 0.8% 12.
2. If this patient develops progression, what is the risk of
dying from EAC?
Second, the clinically relevant endpoint that should be
prevented is progression to advanced, symptomatic EAC
and/or EAC-related death. Most endoscopic studies define
recurrent HGD or worse as an endpoint, or even recurrent
LGD. Although this might be a logic endpoint for some stud-
ies, this is not the relevant endpoint that matters to a patient.
Proper data describing the natural history of HGD or early
EAC is lacking, but older studies report incidence rates of
HGD to advanced EAC of 6.6% per patient year with 2- to
5-year duration between detection of HGD and development
of advanced EAC 30, 31. Based on a worst-case scenario in
which all patients would have died due to advanced EAC 2
years after progression was detected but not treated, we
adapted the factual curve for progression from our study by
0 12 24 36 48 60 72 84 96
94 65 39 25 18 9 7 6 5
Fig. 4 Risk for progression to
HGD/EAC and unrelated death
after ER monotherapy.
Cumulative incidence curves for
progression to HGD/EAC and
unrelated death during long-term
FU after ERmonotherapy, among
the 73 patients in which RFA was
not initiated due to older age and/
or comorbidity
Fig. 3 Long-term outcomes for 73 patients with no ablation due to older age and/or comorbidity. The outcomes during endoscopic follow-up, and long-
term follow-up for vital status, among the 73 patients where RFA was not initiated due to older age and/or comorbidity
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horizontally shifting it two years to the right (Fig. 5). This new
curve now represents the imaginary incidence for EAC-
related death in the study population. This plot is based on
numerous assumptions and should not be adopted for truth,
but merely provides insight in the differences of occurrence
and timing for varying endpoints used.
3. How does the risk for EAC-related death relate to the risk
of death due to other causes?
Finally, the benefits of eradication of all BE over removal
of neoplasia should be balanced against the assumed life ex-
pectancy of a patient. Differences in life expectancywould not
only change the cumulative risk for recurrence as described
above but would also change the curve for unrelated death in
Fig 5. For young and fit patients, this curve would shift down-
wards, whereas it would be steeper along with increasing age
and/or comorbidity. The actual decision to eradicate the re-
maining BE after ER should be based on a balance between
the risk of future progression to advanced EAC versus the risk
for death due to other causes.
What is an acceptable surveillance interval after ER
monotherapy? We detected all progressors at early stages,
and we found no progression within the first 18 months
post-ER. This suggests that annual surveillance is an ac-
cepted strategy and that we can safely perform the first
FU endoscopy 1 year after confirmation of a completely
flat BE post-ER. On the other hand, in older patients with
a short remaining BE segment, we may stop endoscopic
Table 3 Univariable analysis for progression
No progression N = 77 Progression N = 17 FG HR [95% CI] Cox HR [95% CI]
Demographics Age, years (mean (± SD)) 75 (9) 71 (11) 1.01 [0.94; 1.04] 1.01 [0.95; 1.04]
Male gender, n (%) 52 (68) 12 (71) 0.82 [0.43;3.47] 0.91 [0.32; 2.60]
Baseline BE Worst ER histology, n (%) 2.53 [0.29; 22.3] 1.90 [0.25; 14.67]
LGD 8 (10) 1 (6)
HGD/EAC 69 (90) 16 (94)
N ER specimen 2 (1–3) 2 (1–3) 0.94 [0.67; 1.30] 0.99 [0.72; 1.36]
Residual BE Circumferential extent, cm (median (IQR)) 2 (0–5) 5 (2–6) 1.11 [1; 1.23] 1.22 [1.08; 1.40]
Maximum extent, cm (median (IQR)) 5 (2–8) 6 (5–8) 1.09 [0.98; 1.21] 1.13 [0.98; 1.30]
Worst histology, n (%) 2.17 [0.77; 6.18] 2.47 [0.68; 8.99]
NDBE/LGD 63 (82) 14 (82)
HGD 3 (4) 3 (18)
No histology 11 (14) –
Univariable analysis for demographic and treatment characteristics for prediction or progression to HGD or EAC during endoscopic FU, assessed with
Cox analysis and Fine and Gray estimation
EAC esophageal adenocarcinoma, ER endoscopic resection, ER endoscopic resection, FG Fine and Gray, HGD high-grade dysplasia, IQR interquartile
range, LGD low-grade dysplasia, NDBE non-dysplastic Barrett esophagus, SD standard deviation
Fig. 5 Hypothetical risks for
EAC-related death and unrelated
death in the situation where we
would not have treated progres-
sion. Imaginary cumulative inci-
dence curves for EAC-related
death and unrelated death. The
incidence curve for EAC-related
was derived from the assumption
that progression that was left un-
treated would cause EAC-related
death 2 years later
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FU directly after ER, based on the aforementioned
considerations.
Finally, if a patient has predictors for a low success chance
after RFA, such as BE regeneration of the ER scar or a long
BE without any squamous islands 26, one may decide not to
start RFA but perform surveillance instead, independent of a
patient’s life expectancy.
This is the first study that provides long-term FU data for
an alternative treatment strategy in older patients with BE-
related neoplasia. In our cohort of patients treated in a central-
ized setting by experienced endoscopists, this constituted 10%
of the population that qualified for RFA after ER according to
current guidelines. The suggested ER monotherapy strategy is
advised in patients with a life expectancy of < 5–10 years and
should be considered for a life expectancy of < 15–20 years.
We suggest to consider and discuss this strategy in patients
aged > 70 years and those with severe comorbidity.
Some limitations need to be addressed. The median dura-
tion of endoscopic FU was 21 months, while the median time
to progression was 26 months, and all progressors occurred at
minimal 18 months after ER. In light of this, we performed
analysis that only included patients with FU over 18 months,
which showed a minimally increased annual progression risk
(i.e., 8.0% for all patients and 8.6% for patients with FU > 18
months). Still, if we would have had longer endoscopic FU,
the annual progression risk might potentially have increased
with a peak after longer FU, suggesting that the progression
risk is not constant over time but increased over the years.
Unfortunately, our data are too limited for solid analysis of
this aspect. On the other hand, we report results for patients
with limited life expectancy, and ultra-long-term FU data
therefore have no clinical consequences. This is reflected by
the fact that only one-third of patients was still under endo-
scopic surveillance at the moment of data collection. The
others had already died of other causes (one-third) or were
alive after endoscopic FU was already stopped (one-third).
Therefore, extended FU with a potentially higher progression
rate would not have changed the long-term outcomes, mortal-
ity rates, or our conclusions and recommendations.
Other limitations include the low number of events to as-
sess predictive factors, which limited us to perform
univariable analysis only. The FU duration for vital status
may have been too short to detect recurrent, symptomatic
disease among those patients whose FU was stopped early.
A total of 7 patients had no endoscopic FU and were only
assessed for vital status.
We are currently working on clinical prediction tools to
provide individualized, evidence-based advices on optimal
FU strategy after ER and/or RFA, taking account of the risk
for progression and EAC-related death on the one hand, and
patient age, comorbidity, and risk for unrelated death on the
other. These data might help in defining the optimal strategy
after ER monotherapy in the future.
In conclusion, ER monotherapy with endoscopic surveil-
lance of the residual flat BE is a valid alternative to prophy-
lactic ablation therapy of residual BE, in selected patients.
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